Home › Funds › Merck & Co., Inc. › XLO

Merck & Co., Inc. position in XLO

XILIO THERAPEUTICS INC · Health Care

Merck & Co., Inc. reported holding 105,982 shares of XLO (XILIO THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$959K, representing 0.12% of its reported portfolio and ranking #11 among its reported holdings. Merck & Co., Inc. has disclosed XLO holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

Latest position (Q3 2026)105.98K sh
Reported value held$959.14K
Portfolio Weight0.12%
First reportedQ4 2024
Last changeHold
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Merck & Co., Inc.'s XLO position evolved

Merck & Co., Inc. first disclosed a stake in XLO in Q4 2024 at 1,483,758 shares (US$1.4M). Across 8 filings, Merck & Co., Inc. increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 105,982 shares valued at US$959K. Notable position changes include a 93% trim in Q1 2026 (shares rose 14% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2024 1.48M $1.42M New
Q1 2025 1.48M $1.07M Hold
Q2 2025 1.48M $1.01M Hold
Q3 2025 1.48M $1.25M Hold
Q4 2025 1.48M $949.90K Hold
Q1 2026 105.98K $891.31K Reduce
Q2 2026 105.98K $1.02M Hold
Q3 2026 105.98K $959.14K Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About XLO and 13F data

XLO (XILIO THERAPEUTICS INC) is a Health Care company. 26 other funds we track also report a position in XLO — the largest reported positions include Bain Capital Life Sciences Investors, LLC (US$6.4M), GILEAD SCIENCES, INC. (US$5.9M), Frazier Life Sciences Management, L.P. (US$4.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding XLO

All XLO fund holders →

FAQ

How long has Merck & Co., Inc. held XLO?

Merck & Co., Inc. has disclosed XLO holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

What is Merck & Co., Inc.'s current position in XLO?

As of Q3 2026, Merck & Co., Inc. holds 105.98K shares of XLO (XILIO THERAPEUTICS INC), valued at $959.14K, representing 0.12% of its reported portfolio and ranking #11.

Has Merck & Co., Inc. been buying or selling XLO?

In the latest 13F filing (Q3 2026), Merck & Co., Inc. held unchanged its position in XLO.

Which other funds hold XLO?

Other major institutional holders of XLO include Bain Capital Life Sciences Investors, LLC, GILEAD SCIENCES, INC., Frazier Life Sciences Management, L.P., among 26 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.